EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Beyond the P Value: A Systematic Framework for Interpreting Oncology Clinical Trials

Ruyue Li, Xue Dong, Xiujing Yao, Wenjie Chen, Hao An, Yintao Li iD

JCO Precision Oncology · 2026-08 · 10 (8)

DOI: 10.1200/po-26-00271 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JCO Precision Oncology, 2026-08. Verfasst von Ruyue Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, …. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Medical Oncology, Neoplasms. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In oncology, interpreting clinical trials solely through statistical significance ( P < .05) often conflates true biological futility with methodological false negatives. This binary oversimplification risks prematurely abandoning active therapies while wasting resources on futile programs. We aimed to develop a structured framework to evaluate late-phase trials beyond simple P value assessments. Through a critical review of literature and landmark late-phase oncology trials, we analyzed common failure mechanisms and methodological pitfalls to construct a comprehensive, three-step methodology for the post hoc evaluation of negative studies. The review yielded a synthesized framework that approaches trial interpretation through three sequential steps. First, classification stratifies trials into five distinct categories: true negatives, false negatives, inconclusive trials, positive but irrelevant results, and nonsuperior but clinically valuable. Second, diagnosis uses root-cause analysis to identify underlying trial design flaws, execution biases, or statistical pitfalls. Third, recommendations outline targeted actionable strategies, including trial redesign, supplementary biomarker validation, precision medicine approaches, or scientific confirmation of therapeutic futility. This framework shifts trial interpretation from a simple win/loss assessment to a nuanced, value-based strategy. By systematically dissecting the root causes of trial failures, it empowers researchers to rescue therapies with latent clinical benefit or confidently confirm futility, thereby optimizing the evidence landscape for precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicMedical OncologyNeoplasmsHumansResearch DesignPrecision MedicineData Interpretation, Statistical

Autor:innen und Institutionen

  • Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China.
  • School of Clinical Medicine, Weifang Medical University, Weifang, China.

ORCID-Profile: Yintao Li

Zitieren

APA

Li, R., Dong, X., Yao, X., Chen, W., An, H., & Li, Y. (2026). Beyond the P Value: A Systematic Framework for Interpreting Oncology Clinical Trials. JCO Precision Oncology, 10(8). https://doi.org/10.1200/po-26-00271

Vancouver

Li R, Dong X, Yao X, Chen W, An H, Li Y. Beyond the P Value: A Systematic Framework for Interpreting Oncology Clinical Trials. JCO Precision Oncology. 2026;10(8). doi:10.1200/po-26-00271

BibTeX
@article{Li2026,
  author = {Li, Ruyue and Dong, Xue and Yao, Xiujing and Chen, Wenjie and An, Hao and Li, Yintao},
  title = {Beyond the P Value: A Systematic Framework for Interpreting Oncology Clinical Trials},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {8},
  doi = {10.1200/po-26-00271}
}
Kostenlos starten →